AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

PET-MRI of Reward System in Parkinson's Disease With RBD

RecruitingNAAges 45 Years - 80 YearsAllUniversity Hospital, Clermont-Ferrand
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Impulse control disorders (ICDs) are frequently observed in Parkinson's disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary risk factor for the emergence of ICDs in PD is long-term dopaminergic treatment, but other risk factors, such as rapid eye movement sleep behavior disorder (RBD), have recently been identified. The mechanisms leading to ICDs in PD remain debated, but it has been shown that the dopaminergic mesocorticolimbic pathways play a key role in reward, learning, and reinforcement processes, as well as in the regulation of impulsivity. PET studies using \[11C\]raclopride, a tracer that allows evaluation of the postsynaptic availability of dopamine D2/D3 receptors, have demonstrated abnormal sensitization of the mesocorticolimbic dopaminergic system (the reward system), particularly in the ventral stria

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients aged 45 to 80 years * Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria * Duration of Parkinson's disease progression โ‰ฅ 3 years * Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration * Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol * Patients affiliated with or beneficiaries of a social security system * Volunteer patients capable of providing informed consent to participate in the research Exclusion Criteria: * Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD) * Patients with severe depression (Beck Depression Inventory \\\[20\] (BDI) score \> 30), apathy (Starkstein scale \\\[21\] score โ‰ฅ 14), cognitive impairment (Montreal Cognitive Assessment \\\[MoCA\] \\\[22\] score \< 25). * Patients with impulse control disorders, defined by either of the following: * A score of โ‰ฅ 6 on the "Pathological Gambling" item, โ‰ฅ 8 on the "Compulsive Buying" item, โ‰ฅ 8 on the "Sexual Behavior" item, or โ‰ฅ 7 on the "Eating Behavior" item, and more than one positive response (score \> 0) on the corresponding QUIP-RS items for Gambling, Compulsive Buying, Sexual Behavior, and Eating Behavior. * A total QUIP-RS score โ‰ฅ 10. * Patients with severe motor symptoms: patients with an MDS-UPDRS III score \> 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item โ‰ฅ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement * Patients under guardianship, curatorship, deprived of liberty, or under legal protection * Pregnant or breastfeeding women * Patients with contraindications to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances) * Refusal to participate
๐Ÿ’Š

What it tests

  • PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).
๐Ÿ“

Where

3 sites
CHU Clermont-Ferrand, Clermont-Ferrand,
Clermont-Ferrand, France
CH Le Puy en Velay
Le Puy-en-Velay, France
CHRU Lyon
Lyon, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy